The study examined the device’s effect on pain associated with CIPN that can produce sharp pains in the hands and feet of cancer patients who are undergoing chemotherapy. This debilitating pain affects about 30 to 40 percent of cancer patients treated with chemotherapy and typically develops into a classic stocking-and-glove pain that can last for many years. “Exploring ways to treat pain other than prescribing opioids such as morphine is key to our mission of improving the quality of life for cancer patients,” said Dr. Smith.
Competitive Technologies, Inc. (NYSE Amex:CTT) today announced the issuance of an abstract from a study which has shown the successful treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy (CIPN) using CTT’s Calmare® Pain Therapy Treatment.
Calmare is being used to treat international patients in Italy, India, Greece, Bangladesh, and U.S. patients at clinics in Utah, Texas, Massachusetts, New York, Virginia, Florida, Connecticut and Rhode Island. In addition to treating pain associated with cancer and cancer treatments, Calmare Pain Therapy also successfully treats chronic neuropathic pain resulting from shingles, failed back surgery, phantom limb syndrome, sciatica, spinal stenosis and other maladies.
The purpose of this study is to determine if patients with painful CIPN will have a decrease in pain scores after treatment with the Calmare® MC-5A device.
January 2013, Park
NCT ID: NCT01261780
Sponsor: University of Wisconsin, Madison
Principal Investigator: Toby Campbell
Protocol IDs: OS10328
NCT ID: NCT01196442
Sponsor: Virginia Commonwealth University, Massey Cancer Center
Principal Investigator: Thomas J. Smith
Protocol IDs: MCC-13098, NCI-2010-01945
NCT ID: NCT01347723
Sponsor: Mayo Clinic
Principal Investigator: Charles L. Loprinzi
Protocol IDs: MC10CC, NCI-2011-00339